$28.6B
35.1
$2.09
| Дата | Имя | Тип | Акции | Цена |
|---|---|---|---|---|
| 26.02 | Osterloh Albert Frederick IV | Sell | 0 | $0.00 |
| 26.02 | Osterloh Albert Frederick IV | Sell | 7,061 | $0.00 |
| 26.02 | Osterloh Albert Frederick IV | Sell | 0 | $0.00 |
| 17.02 | Heller Bridgette P | Sell | 1,012 | $68.01 |
| 02.02 | Leach Jacob Steven | Sell | 8,310 | $0.00 |
| 02.02 | Brown Michael Jon | Sell | 7,123 | $0.00 |
| 02.02 | Stern Sadie | Sell | 7,123 | $0.00 |
| 02.02 | Sylvain Jereme M | Sell | 2,652 | $73.36 |
| 02.02 | Brown Michael Jon | Sell | 2,653 | $73.36 |
| 02.02 | Sylvain Jereme M | Sell | 7,123 | $0.00 |
| 02.02 | SAYER KEVIN R | Sell | 34,257 | $73.36 |
| 02.02 | SAYER KEVIN R | Sell | 71,218 | $0.00 |
| 02.02 | Leach Jacob Steven | Sell | 3,058 | $73.36 |
| 02.02 | Stern Sadie | Sell | 2,656 | $73.36 |
| 17.11 | Collins Richard Alexander | Sell | 2,906 | $59.05 |
| 12.11 | Heller Bridgette P | Sell | 1,012 | $58.07 |
| 10.11 | Collins Richard Alexander | Sell | 3,948 | $55.17 |
| 10.11 | Leach Jacob Steven | Sell | 15,700 | $54.98 |
| 10.11 | Leach Jacob Steven | Sell | 2,500 | $55.43 |
| 28.10 | Ashley Euan A. | Sell | 7,166 | $0.00 |
Данные за последние 90 дней. Источник: SEC Filings.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Отказ от ответственности: Данные предоставлены Financial Modeling Prep API. Информация носит справочный характер и не является инвестиционной рекомендацией. Котировки могут обновляться с задержкой до 15 минут.
